Evidence map›Paper›PMID 27335215›Full record

ArticleJournal of chemical information and modeling2016

Machine Learning Model Analysis and Data Visualization with Small Molecules Tested in a Mouse Model of Mycobacterium tuberculosis Infection (2014-2015).

Sean Ekins, Alexander L Perryman, Alex M Clark, Robert C Reynolds, Joel S Freundlich

Abstract read
In one paragraph

Article in Journal of chemical information and modeling, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Machine Learning Models forMolecular pharmaceutics · 2022
    Article
  4. Mycobacterium abscessus drug discovery using machine learning.Tuberculosis (Edinburgh, Scotland) · 2022
    Article
  5. Article
  6. Review
  7. Article
  8. Molecule Property Analyses of Active Compounds forJournal of medicinal chemistry · 2020
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Sean EkinsCollaborative Drug Discovery , 1633 Bayshore Highway, Suite 342, Burlingame, California 94010, United States.
Alexander L PerrymanDepartment of Pharmacology, Physiology and Neuroscience, Rutgers University-New Jersey Medical School , Newark, New Jersey 07103, United States.
Alex M ClarkMolecular Materials Informatics, Inc. , 1900 St. Jacques #302, Montreal, Quebec H3J 2S1, Canada.
Robert C ReynoldsDivision of Hematology and Oncology, Department of Medicine, and Department of Chemistry, College of Arts and Sciences, University of Alabama at Birmingham , 1530 Third Avenue South, Birmingham, Alabama 35294-1240, United States.
Joel S FreundlichDepartment of Pharmacology, Physiology and Neuroscience, Rutgers University-New Jersey Medical School , Newark, New Jersey 07103, United States.
Rutgers New Jersey Medical SchoolCollaborations Pharmaceuticals (United States) · USUniversity of Alabama at Birmingham · US

Funding

Therapeutics for drug resistant-bacteria: Arylpropionyl-phloroglucinolsU19AI109713 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI ALLAND, DAVID · 2014 to 2018
$26.9M
Biocomputation across distributed private datasets to enhance drug discoveryR44TR000942 · NCATS · COLLABORATIVE DRUG DISCOVERY, INC. · PI BUNIN, BARRY A · 2013 to 2018
$2.9M
Identification of novel therapeutics for tuberculosis combining cheminformatics,R42AI088893 · NIAID · COLLABORATIVE DRUG DISCOVERY, INC. · PI EKINS, SEAN · 2012 to 2013
$997k
NCATS NIH HHS R44 TR000942NIAID NIH HHS R42 AI088893NIAID NIH HHS U19 AI109713
6 · The paper itself

Abstract

The renewed urgency to develop new treatments for Mycobacterium tuberculosis (Mtb) infection has resulted in large-scale phenotypic screening and thousands of new active compounds in vitro. The next challenge is to identify candidates to pursue in a mouse in vivo efficacy model as a step to predicting clinical efficacy. We previously analyzed over 70 years of this mouse in vivo efficacy data, which we used to generate and validate machine learning models. Curation of 60 additional small molecules with in vivo data published in 2014 and 2015 was undertaken to further test these models. This represents a much larger test set than for the previous models. Several computational approaches have now been applied to analyze these molecules and compare their molecular properties beyond those attempted previously. Our previous machine learning models have been updated, and a novel aspect has been added in the form of mouse liver microsomal half-life (MLM t1/2) and in vitro-based Mtb models incorporating cytotoxicity data that were used to predict in vivo activity for comparison. Our best Mtb in vivo models possess fivefold ROC values > 0.7, sensitivity > 80%, and concordance > 60%, while the best specificity value is >40%. Use of an MLM t1/2 Bayesian model affords comparable results for scoring the 60 compounds tested. Combining MLM stability and in vitro Mtb models in a novel consensus workflow in the best cases has a positive predicted value (hit rate) > 77%. Our results indicate that Bayesian models constructed with literature in vivo Mtb data generated by different laboratories in various mouse models can have predictive value and may be used alongside MLM t1/2 and in vitro-based Mtb models to assist in selecting antitubercular compounds with desirable in vivo efficacy. We demonstrate for the first time that consensus models of any kind can be used to predict in vivo activity for Mtb. In addition, we describe a new clustering method for data visualization and apply this to the in vivo training and test data, ultimately making the method accessible in a mobile app.

Indexed as

Machine LearningAnimalsBayes TheoremComputational BiologyDisease Models, AnimalDrug DiscoveryMiceMycobacterium tuberculosisTuberculosis

Identifiers

PMID27335215
PMCPMC4962118
OpenAlexW2473066820

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.